Addex Therapeutics
ADXN
3 hedge funds and large institutions have $778K invested in Addex Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 6 closing their positions.
0.24% less ownership
Funds ownership: 0.26% → 0.02% (-0.24%)
44% less capital invested
Capital invested by funds: $1.39M → $778K (-$610K)
57% less funds holding
Funds holding: 7 → 3 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$191K |
| 2 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$3.97M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$114K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$62.2K |
| 4 |
VF
Virtu Financial
New York
|
-$41K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$32.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $633K | -$3.97M | -273,435 | -97% |
|
|
AC
2
Armistice Capital
New York
| $138K | +$191K | +13,200 | New |
|
|
BBA
3
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| $7.93K | +$14.2K | +981 | New |
|
|
ECM
4
Endurant Capital Management
San Mateo,
California
| – | -$114K | -6,037 | Closed |
|
|
OMC
5
Old Mission Capital
Chicago,
Illinois
| – | -$62.2K | -3,286 | Closed |
|
|
VF
6
Virtu Financial
New York
| – | -$41K | -2,146 | Closed |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$32.5K | -1,719 | Closed |
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$14.3K | -754 | Closed |
|
9
Jane Street
New York
| – | -$11K | -583 | Closed |
|
ADXN Hedge Fund Activity: Q2 2023 in Review
3 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q2 2023, worth a combined $778K — down 44% from $1.39M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ADXN and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $191K. The largest seller was NEA Management Company, cutting an estimated $3.97M.
- 3 institutional investors held Addex Therapeutics (ADXN) as of Q2 2023, down from 7 in Q1 2023.
- Funds reported $778K of Addex Therapeutics stock for Q2 2023, down 44% quarter-over-quarter.
- 2 funds opened new Addex Therapeutics positions in Q2 2023 and 6 closed out, a net change of -4 holders.
- The largest Addex Therapeutics buyer in Q2 2023 was Armistice Capital, an estimated $191K added.
- The largest Addex Therapeutics seller in Q2 2023 was NEA Management Company, an estimated $3.97M sold.
Based on aggregated 13F filings for Q2 2023.